Analysis of anti-microbial resistance of Escherichia coli that caused infection in urogenital system

Abstract

Abstract: Objective To study the anti-microbial resistance of Escherichia coli (E.coli) that caused infection in urogenital system. Method Anti-microbial susceptibility tests for 148 strains of E.coli were conducted by disc diffusion technique. Results In 28 commonly used antibiotics, the resistance rates of E.coli to β-lactam and quinolones were high (73.6%-86.4%). High resistance rates to the first- and the second-generation cephalosporin (cefradime, cephazolin and cefaclor) were also observed (44%). Resistance rate to ceftazidime is the lowest (10.1%) in the third-generation cephalosporin. The resistance rates of E.coli to piperacillin, pefoperazone and ampicillin were 84.5%, 44.6% and 83.0% respectively. Combined antibiotic and β-lactam inhibitor gave lower resistance rates than antibiotic alone (piperacillin/tazobactam, cefoporazone/sulbactam and ampicillin/sulbactam were 4.1%, 10.8% and 52.0% respectively, P<0.01). Of 148 E.coli isolates, 38 strains were capable of yielding extended-spectrum beta-lactamases (ESBLs) (25.7%), 110 strains were not able to produce ESBLs (74.3%) and the resistance rates of isolates with ESBLs to 28 antibiotics were significantly lower than those of isolates without ESBLs. Conclusion Antibiotic/β-lactam inhibitor and nitrofurantoin are effective for urogenital infections caused by E.coli.

CLC Number:

R978.1

CUI Wei-li, XU De-xing, LI Wen-ling, WANG Lu-xia. Analysis of anti-microbial resistance of Escherichia coli that caused infection in urogenital system[J]. Journal of Southern Medical University, 2004, 24(08): 940-942,945.

References

[1] 唐明忠,刘娟,王美容.尿中大肠埃氏希菌耐药特性的调查[J].中华医院感染学杂志(Chin Hosp Infec J),1998,3(8):119-20.
[2] National Committee for Clinical Laboratory Standards (NCCLS).Performance standards for antimicrobial susceptibility testing[J].Ninth Informational Supplement M 100-S11,2001, 21: 1-122.
[3] Li JT, Weinstein A J, Yang M, et al. Surveillance of bacterial resistance in China (1998～1999)[J]. 中华医学杂志(Natl Med J Chin)2001, 81(1): 8.
[4] 张亚莉,耿穗娜,赖福才,等.常见病原菌对环丙沙星的耐药现状[J].第一军医大学学报,2002,22(4):378-9.Zhang YL, Geng SN, Lai FC, et al. Survey on drug resistance to ciprofloxacin in common pathogenic bacteria[J]. J Firs Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002, 22(4): 378-9.
[5] 冯玉华,崔维韵,李奇志,等.泌尿系感染大肠埃希氏菌耐药性分析[J].天津药学(Tianjing Pharmaco),2002,14(6):69-70.
[6] 王露霞,石凌波,徐德兴,等.应用纸片扩散法与梯度浓度法测定不动杆菌属的耐药性[J].第一军医大学学报,2003,23(5):469-71.Wang LX, Shi LB, Xu DX, et al. Assay ofAcinetobacter SPP drug-resistance by Kirby-Bauer and Etest method[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(5): 469-71.
[7] Jacoby GA, Medeiros AA. More extended-spectrum β-1actamases[J]. Antimicrob Agents Che mother, 1991, 35(9): 1697
[8] Pogne DJ, Amyes SGB. Transferable resistance to extended spectrum β-1actams:a major threat or a minor inconvenience[J]? J Antimicrob Chemother, 1991, 27(2): 255.
[9] Medeiros AA. Evolution and dissemination ofbeta-lactamases accelerated by generation of beta-lactam antibiotics[J]. Clin infect Dis,1997, 24(Suppl 1): S19.
[10] Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases[J]. Antibim icrob Agents Chem other, 1989, 33:1131.
[11] Firere J, Guiney D. Extended-spectrum beta-lactamases[J]. J Am Med Assos, 1999, 281: 563.
[12] Jacoby GA, Hah P. Detection of extended-spectrum beta-lactam ases in clinical is o lates ofK lebsiella p neumoniae and E scherichia coli[J]. J Clin Microbiol, 1996, 34: 908.